# Davita Inc.: financial statements, quarterly

DVA · NYSE · CIK 927066 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dva.md) · [Financials](/companies/dva/financials.md) · [Filings](/companies/dva/filings.md) · [Insiders](/companies/dva/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dva/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,146 d](/filings/0000927066-26-000012.md) | [3,071](/filings/0000927066-25-000087.md) | [3,187](/filings/0000927066-25-000124.md) | [3,264](/filings/0000927066-25-000165.md) | [3,295 d](/filings/0000927066-26-000012.md) | [3,224](/filings/0000927066-26-000062.md) | [3,380](/filings/0000927066-26-000108.md) | [3,420](/filings/0000927066-26-000134.md) | [3,620 d](/filings/0000927066-26-000012.md) | [3,416](/filings/0000927066-26-000062.md) | [3,554](/filings/0000927066-26-000108.md) | [3,578](/filings/0000927066-26-000134.md) |
| Operating income | $m | [390 d](/filings/0000927066-26-000012.md) | [484](/filings/0000927066-25-000087.md) | [506](/filings/0000927066-25-000124.md) | [535](/filings/0000927066-25-000165.md) | [565 d](/filings/0000927066-26-000012.md) | [439](/filings/0000927066-26-000062.md) | [538](/filings/0000927066-26-000108.md) | [506](/filings/0000927066-26-000134.md) | [561 d](/filings/0000927066-26-000012.md) | [482](/filings/0000927066-26-000062.md) | [579](/filings/0000927066-26-000108.md) | [499](/filings/0000927066-26-000134.md) |
| Income tax | $m | [58.5 d](/filings/0000927066-26-000012.md) | [65.8](/filings/0000927066-25-000087.md) | [71.7](/filings/0000927066-25-000124.md) | [77.7](/filings/0000927066-25-000165.md) | [64.5 d](/filings/0000927066-26-000012.md) | [54.1](/filings/0000927066-26-000062.md) | [93.7](/filings/0000927066-26-000108.md) | [68.6](/filings/0000927066-26-000134.md) | [76.7 d](/filings/0000927066-26-000012.md) | [66.2](/filings/0000927066-26-000062.md) | [91.8](/filings/0000927066-26-000108.md) | [89.3](/filings/0000927066-26-000134.md) |
| Net income | $m | [151 d](/filings/0000927066-26-000012.md) | [240](/filings/0000927066-25-000087.md) | [223](/filings/0000927066-25-000124.md) | [215](/filings/0000927066-25-000165.md) | [259 d](/filings/0000927066-26-000012.md) | [163](/filings/0000927066-26-000062.md) | [199](/filings/0000927066-26-000108.md) | [150](/filings/0000927066-26-000134.md) | [234 d](/filings/0000927066-26-000012.md) | [198](/filings/0000927066-26-000062.md) | [265](/filings/0000927066-26-000108.md) | [223](/filings/0000927066-26-000134.md) |
| Diluted EPS | $ per share | not reported | [2.65](/filings/0000927066-25-000087.md) | [2.50](/filings/0000927066-25-000124.md) | [2.50](/filings/0000927066-25-000165.md) | not reported | [2.00](/filings/0000927066-26-000062.md) | [2.58](/filings/0000927066-26-000108.md) | [2.04](/filings/0000927066-26-000134.md) | not reported | [2.87](/filings/0000927066-26-000062.md) | [4.02](/filings/0000927066-26-000108.md) | [3.40](/filings/0000927066-26-000134.md) |
| Basic EPS | $ per share | not reported | [2.73](/filings/0000927066-25-000087.md) | [2.56](/filings/0000927066-25-000124.md) | [2.56](/filings/0000927066-25-000165.md) | not reported | [2.05](/filings/0000927066-26-000062.md) | [2.62](/filings/0000927066-26-000108.md) | [2.09](/filings/0000927066-26-000134.md) | not reported | [2.93](/filings/0000927066-26-000062.md) | [4.10](/filings/0000927066-26-000108.md) | [3.49](/filings/0000927066-26-000134.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.4](/filings/0000927066-25-000012.md) | [0.3](/filings/0000927066-24-000090.md) | [0.4](/filings/0000927066-24-000128.md) | [1.1](/filings/0000927066-24-000179.md) | [0.8](/filings/0000927066-26-000012.md) | [0.4](/filings/0000927066-25-000087.md) | [0.7](/filings/0000927066-25-000124.md) | [0.7](/filings/0000927066-25-000165.md) | [0.7](/filings/0000927066-26-000134.md) | [0.6](/filings/0000927066-26-000062.md) | [0.7](/filings/0000927066-26-000108.md) | [0.5](/filings/0000927066-26-000134.md) |
| Current assets | $bn | [3.1](/filings/0000927066-25-000012.md) | [3.7](/filings/0000927066-24-000090.md) | [3.5](/filings/0000927066-24-000128.md) | [4.0](/filings/0000927066-24-000179.md) | [3.7](/filings/0000927066-26-000012.md) | [3.6](/filings/0000927066-25-000087.md) | [4.1](/filings/0000927066-25-000124.md) | [4.1](/filings/0000927066-25-000165.md) | [4.1](/filings/0000927066-26-000134.md) | [4.1](/filings/0000927066-26-000062.md) | [4.2](/filings/0000927066-26-000108.md) | [4.1](/filings/0000927066-26-000134.md) |
| Total assets | $bn | [16.9](/filings/0000927066-25-000012.md) | [17.4](/filings/0000927066-24-000090.md) | [17.0](/filings/0000927066-24-000128.md) | [17.5](/filings/0000927066-24-000179.md) | [17.3](/filings/0000927066-26-000012.md) | [17.1](/filings/0000927066-25-000087.md) | [17.5](/filings/0000927066-25-000124.md) | [17.6](/filings/0000927066-25-000165.md) | [17.5](/filings/0000927066-26-000134.md) | [17.5](/filings/0000927066-26-000062.md) | [17.7](/filings/0000927066-26-000108.md) | [17.8](/filings/0000927066-26-000134.md) |
| Current liabilities | $bn | [2.6](/filings/0000927066-25-000012.md) | [2.6](/filings/0000927066-24-000090.md) | [3.0](/filings/0000927066-24-000128.md) | [2.9](/filings/0000927066-24-000179.md) | [3.0](/filings/0000927066-26-000012.md) | [2.9](/filings/0000927066-25-000087.md) | [2.9](/filings/0000927066-25-000124.md) | [3.0](/filings/0000927066-25-000165.md) | [3.1](/filings/0000927066-26-000134.md) | [2.9](/filings/0000927066-26-000062.md) | [2.9](/filings/0000927066-26-000108.md) | [2.9](/filings/0000927066-26-000134.md) |
| Total liabilities | $bn | [14.2](/filings/0000927066-25-000012.md) | [14.8](/filings/0000927066-24-000090.md) | [14.6](/filings/0000927066-24-000128.md) | [15.3](/filings/0000927066-24-000179.md) | [15.2](/filings/0000927066-26-000012.md) | [15.5](/filings/0000927066-25-000087.md) | [15.9](/filings/0000927066-25-000124.md) | [16.2](/filings/0000927066-25-000165.md) | [16.3](/filings/0000927066-26-000134.md) | [16.5](/filings/0000927066-26-000062.md) | [16.6](/filings/0000927066-26-000108.md) | [16.7](/filings/0000927066-26-000134.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [1.1](/filings/0000927066-25-000012.md) | [0.9](/filings/0000927066-24-000090.md) | [0.6](/filings/0000927066-24-000128.md) | [0.4](/filings/0000927066-24-000179.md) | [0.1](/filings/0000927066-26-000012.md) | [(0.3)](/filings/0000927066-25-000087.md) | [(0.4)](/filings/0000927066-25-000124.md) | [(0.6)](/filings/0000927066-25-000165.md) | [(0.7)](/filings/0000927066-26-000134.md) | [(0.8)](/filings/0000927066-26-000062.md) | [(0.8)](/filings/0000927066-26-000108.md) | [(0.6)](/filings/0000927066-26-000134.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [485 d](/filings/0000927066-26-000012.md) | [(135)](/filings/0000927066-25-000087.md) | [799 d](/filings/0000927066-25-000124.md) | [810 d](/filings/0000927066-25-000165.md) | [548 d](/filings/0000927066-26-000012.md) | [180](/filings/0000927066-26-000062.md) | [324 d](/filings/0000927066-26-000108.md) | [842 d](/filings/0000927066-26-000134.md) | [541 d](/filings/0000927066-26-000012.md) | [321](/filings/0000927066-26-000062.md) | [490 d](/filings/0000927066-26-000108.md) | [519 d](/filings/0000927066-26-000134.md) |
| Capital expenditure | $m | [159 d](/filings/0000927066-26-000012.md) | [121](/filings/0000927066-25-000087.md) | [125 d](/filings/0000927066-25-000124.md) | [139 d](/filings/0000927066-25-000165.md) | [171 d](/filings/0000927066-26-000012.md) | [143](/filings/0000927066-26-000062.md) | [121 d](/filings/0000927066-26-000108.md) | [166 d](/filings/0000927066-26-000134.md) | [145 d](/filings/0000927066-26-000012.md) | [102](/filings/0000927066-26-000062.md) | [170 d](/filings/0000927066-26-000108.md) | [159 d](/filings/0000927066-26-000134.md) |
| Share repurchases | $m | [272 d](/filings/0000927066-26-000012.md) | [251](/filings/0000927066-25-000087.md) | [362 d](/filings/0000927066-25-000124.md) | [408 d](/filings/0000927066-25-000165.md) | [365 d](/filings/0000927066-26-000012.md) | [510](/filings/0000927066-26-000062.md) | [284 d](/filings/0000927066-26-000108.md) | [240 d](/filings/0000927066-26-000134.md) | [274 d](/filings/0000927066-26-000012.md) | [196](/filings/0000927066-26-000062.md) | [181 d](/filings/0000927066-26-000108.md) | [73.0 d](/filings/0000927066-26-000134.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [92.5](/filings/0000927066-24-000090.md) | [93.4](/filings/0000927066-24-000128.md) | [94.0](/filings/0000927066-24-000179.md) | [90.5](/filings/0000927066-25-000087.md) | [89.0](/filings/0000927066-25-000124.md) | [85.8](/filings/0000927066-25-000165.md) | [81.3](/filings/0000927066-26-000062.md) | [77.4](/filings/0000927066-26-000108.md) | [73.8](/filings/0000927066-26-000134.md) | [68.9](/filings/0000927066-26-000062.md) | [66.1](/filings/0000927066-26-000108.md) | [65.5](/filings/0000927066-26-000134.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 62,900,000 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0000927066-26-000134.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 20:16 ET. No prices; not investment advice.